1. Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review
- Author
-
Yingting Zhou, Peixin Huang, and Yi Chen
- Subjects
Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Antibodies, Monoclonal, Humanized ,Targeted therapy ,Cholangiocarcinoma ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Apatinib ,Prospective Studies ,Intrahepatic Cholangiocarcinoma ,business.industry ,Gastroenterology ,Recurrent Intrahepatic Cholangiocarcinoma ,Immunotherapy ,Middle Aged ,Radiation therapy ,Clinical trial ,Bile Ducts, Intrahepatic ,030104 developmental biology ,Bile Duct Neoplasms ,chemistry ,030220 oncology & carcinogenesis ,Lenvatinib ,business - Abstract
Purpose Intrahepatic cholangiocarcinoma is the second most common primary liver cancer, and is associated with a poor prognosis and rising incidence rate. Methods Here, we reported the case of a middle-aged Asian male who presented with a 9.5-cm liver lesion and was diagnosed with intrahepatic cholangiocarcinoma. Results The patient experienced recurrence three times, twice following radical resection and standard adjuvant chemotherapy and once following camrelizumab plus apatinib, after which the tumor progressed with elevated CA 19.9 level. After tissue biopsy for next-generation sequencing, apatinib was replaced by lenvatinib, and the patient achieved disease control again, with a progression-free survival of 10 months. Conclusion Combined immunotherapy and targeted therapy regimens are a promising approach for refractory intrahepatic cholangiocarcinoma. Further well-designed prospective clinical trials are needed to confirm the efficacy and safety. Since intrahepatic cholangiocarcinoma is characterized by high heterogeneity and with complex crosstalk among oncogenic pathways, further exploration is required to more deeply understand the mechanism of action of this treatment approach and guide individualized treatment selection.
- Published
- 2021